Drug Profile

NW 301D

Alternative Names: NW-301D

Latest Information Update: 09 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Neowise Biotechnology
Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

04 May 2025 Peking University plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater, Monotherapy) in China (IV, Infusion), in May 2025 , (NCT06956261)
30 Jun 2024 Wuhan Union Hospital and Neowise Biotechnology initiates enrolment in a phase I trial for Solid tumour (Late-stage disease, Monotherapy, Second-line therapy or greater) in China (NCT06484556)
08 Apr 2024 Phase-I clinical trials in Solid tumours (Second-line therapy or greater) in China (Parenteral) (NCT06484790)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com